dDAVP is a stable analog of vasopressin and it is widely applied clinically to treat bleeding disorders, nocturnal polyuria, and central diabetes insipidus due to the antidiuretic properties mediated by the V2R (Mannucci, 1997; Kapić et al., 2005; Weiss and Everaert, 2019). The gene discussed is AVPR2; the disease is hemorrhagic disease.